


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

November 29, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

#10/43  
Harry  
Dec. 13, 00  
PATENT  
Attorney Docket No.: 17634-000512US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brian R. Murphy, et al.

Application No.: 09/444,067

Filed: November 19, 1999

For: PRODUCTION OF ATTENUATED  
RESPIRATORY SYNCYTIAL VIRUS  
VACCINES FROM CLONED  
NUCLEOTIDE SEQUENCES

Examiner: B. Brumback

Art Unit: 1642

RECEIVED

DEC 11 2000

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO  
RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement mailed June 29, 2000, which set forth the following groups of claims:

- I. Claims 63-69, 120-122, 162, and 163, drawn to recombinant RSV with a gene deletion and to a method of making, classified in class 435 subclass 235.1.
- II. Claims 63, 70-78, and 120-122, drawn to recombinant RSV wherein expression of a selected gene is reduced or ablated, classified in class 435, subclass 235.1.
- III. Claims 63, 79-87, and 120-122, drawn to recombinant RSV wherein the position of one or more genes is altered relative to an RSV promotor, classified in class 435, subclass 235.1.
- IV. Claims 63, 88-95, and 120-122, drawn to recombinant RSV with a modification modulating a change in phenotype or with attenuating mutations, classified in class 424, subclass 199.1.